. Author manuscript; available in PMC: 2018 Jun 27.

Published in final edited form as: Biol Blood Marrow Transplant. 2016 Oct 3;23(2):211–234. doi: 10.1016/j.bbmt.2016.09.023

Table 3.

Potential Agents for Blockading Effects of Innate Immune Response

Target	Agent	Effects	Species	Ref
TLR4	NI-0101	TLR4 specific antibody	mouse	(323)
TLR7, TLR9	AT791; E6446	Small molecule inhibitor	mouse	(324)
MyD88	ST2825	Small molecule inhibitor	mouse	(325)
MyD88	Imatinib	Blocks TLR agonist effect	mouse	(326)
P2X7R	A-438079 CE-224,535	Selective P2X7R antagonists	mouse; man	(327)
NLRP3	Pirfenidone	Inhibits NLRP3 expression	mouse	(328)
NLRP3	Glyburide	Blocks NLRP3 activity	mouse	(329)
IL-1β	Rilonacept	IL-1R1 fusion protein	man
	Canakinumab	Anti-IL-1β	man	(330)
	VX-765, Parthenolide	Caspase-1 inhibitor	man; mouse	(331, 332)
IFNα	Anti-IFNα	Reduce BAFF, CXCL9/10	man	(333, 334)
JAK	Baracitinib, Ruxolitinib, INCB018424, CYT387 (JAK1,2)	Block JAK/STAT signaling of multiple cytokines, including IFN (IFNα/β, IFNγ), gp130 family (IL-6), IL12/IL23, γc family (IL-2, IL-4, IL-7, IL-15)	man; mouse	(60, 97)
JAK	Tofacitinib (JAK1,2,3)	Block JAK/STAT signaling of multiple cytokines, including γc family (IL-2, IL-4, IL-7, IL15)	man; mouse	(335)